The Patent Finder

Byondis B.V.

25 patents currently held · Updated Nov 15, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Previously recorded as Synthon Biopharmaceuticals B.V. (to 2020)

2
Ending by 2030
Nov 2029
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 11, 2027
    The maintenance fee for Dual conjugation process for preparing antibody-drug conjugates (US 11,696,958) comes due Jan 11, 2027. Unpaid by Jul 12, 2027, it lapses early.
  • 1 fee due Feb 8, 2027
    The maintenance fee for Anti-Sirp Alpha Antibodies (US 11,718,681) comes due Feb 8, 2027. Unpaid by Aug 9, 2027, it lapses early.
  • 1 fee due Mar 10, 2027
    The maintenance fee for Site-Specific Conjugation of Linker Drugs to Antibodies and Resulting Adcs (US 10,407,743) comes due Mar 10, 2027. Unpaid by Sep 10, 2027, it lapses early.
  • 1 fee due Sep 30, 2027
    The maintenance fee for Duocarmycin Adcs Showing Improved in Vivo Antitumor Activity (US 10,603,387) comes due Sep 30, 2027. Unpaid by Mar 31, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 9,815,784CC-1065 analogs and their conjugates
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,889,868CC-1065 analogs and their conjugates
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,052,155Conjugates of CC-1065 analogs and bifunctional linkers
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,845,338Method of purifying an antibody
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,890,159Process for making duocarmycin prodrugs
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,421,278Duocarmycin Adcs Showing Improved in Vivo Antitumor Activity
In force
 · High confidence
In forceHigh confidence
US 9,427,480Duocarmycin Adcs for Use in Treatment of Endometrial Cancer
In force
 · High confidence
In forceHigh confidence
US 10,603,387Duocarmycin Adcs Showing Improved in Vivo Antitumor Activity
In force
 · High confidence
In forceHigh confidence
US 10,266,606Method for purifying Cys-linked antibody-drug conjugates
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,407,743Site-Specific Conjugation of Linker Drugs to Antibodies and Resulting Adcs
In force
 · High confidence
In forceHigh confidence
10 of 25 patents shown.
Pro members see all 25.
Pro members: see all 25 patents
Also on record, not counted in the 25: 8 lapsed for an unpaid fee · 1 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending · 2 abandoned · 2 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited